DK2929880T3 - Terapeutisk middel til sygdom baseret på hæmmende effekt af makrofag-migrationshæmmende faktor - Google Patents

Terapeutisk middel til sygdom baseret på hæmmende effekt af makrofag-migrationshæmmende faktor

Info

Publication number
DK2929880T3
DK2929880T3 DK14826811.3T DK14826811T DK2929880T3 DK 2929880 T3 DK2929880 T3 DK 2929880T3 DK 14826811 T DK14826811 T DK 14826811T DK 2929880 T3 DK2929880 T3 DK 2929880T3
Authority
DK
Denmark
Prior art keywords
therapeutic agent
disease based
macrophage migration
inhibitory effect
inhibitory
Prior art date
Application number
DK14826811.3T
Other languages
English (en)
Inventor
Keiichi Tanaka
Kimiko Morimoto
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Application granted granted Critical
Publication of DK2929880T3 publication Critical patent/DK2929880T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/24Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK14826811.3T 2013-07-18 2014-07-17 Terapeutisk middel til sygdom baseret på hæmmende effekt af makrofag-migrationshæmmende faktor DK2929880T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013149690 2013-07-18
PCT/JP2014/069026 WO2015008827A1 (ja) 2013-07-18 2014-07-17 マクロファージ遊走阻止因子の阻害作用に基づく疾患の治療剤

Publications (1)

Publication Number Publication Date
DK2929880T3 true DK2929880T3 (da) 2017-01-02

Family

ID=52346269

Family Applications (2)

Application Number Title Priority Date Filing Date
DK14826811.3T DK2929880T3 (da) 2013-07-18 2014-07-17 Terapeutisk middel til sygdom baseret på hæmmende effekt af makrofag-migrationshæmmende faktor
DK16169414.6T DK3078372T3 (da) 2013-07-18 2014-07-17 Terapeutisk middel mod sygdom på basis af hæmmende virkning af makrofag-migrationshæmmende faktor

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK16169414.6T DK3078372T3 (da) 2013-07-18 2014-07-17 Terapeutisk middel mod sygdom på basis af hæmmende virkning af makrofag-migrationshæmmende faktor

Country Status (22)

Country Link
US (3) US20150353519A1 (da)
EP (2) EP3078372B1 (da)
JP (2) JP5802868B2 (da)
CN (1) CN105407887B (da)
AU (1) AU2014291149B2 (da)
CA (1) CA2918325C (da)
CY (2) CY1118140T1 (da)
DK (2) DK2929880T3 (da)
ES (2) ES2642440T3 (da)
HR (2) HRP20161317T1 (da)
HU (2) HUE029800T2 (da)
IL (1) IL243550B (da)
LT (2) LT2929880T (da)
NO (1) NO3078372T3 (da)
PL (2) PL2929880T3 (da)
PT (2) PT3078372T (da)
RS (2) RS56489B1 (da)
RU (2) RU2750540C2 (da)
SI (2) SI3078372T1 (da)
SM (3) SMT201700080T1 (da)
TW (1) TWI603965B (da)
WO (1) WO2015008827A1 (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6901571B2 (ja) * 2017-01-26 2021-07-14 四川瀛瑞医薬科技有限公司Sichuan Yingrui Pharmaceutical Technology Company ナノ炭素−鉄複合システム及びその組成物、調製方法並びに使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0753725B2 (ja) 1987-10-08 1995-06-07 富山化学工業株式会社 4h―1―ベンゾピラン―4―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤
EP0695547B1 (en) 1993-04-09 2001-08-08 Toyama Chemical Co., Ltd. Immunomodulator, cell adhesion inhibitor, and agent for treating and preventing autoimmune diseases
EP0868598B1 (de) * 1995-12-21 1999-10-27 Siemens Aktiengesellschaft Luftansaugvorrichtung mit variabler saugrohrlänge für eine brennkraftmaschine
DE10044091A1 (de) * 2000-09-07 2002-04-04 Merck Patent Gmbh Chromanonderivate
GB0507695D0 (en) 2005-04-15 2005-05-25 Novartis Ag Organic compounds
GB0507696D0 (en) * 2005-04-15 2005-05-25 Novartis Ag Organic compounds
EP1940382A2 (en) * 2005-10-07 2008-07-09 Aditech Pharma AB Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
RU2611341C2 (ru) 2011-08-30 2017-02-21 Тояма Кемикал Ко., Лтд. Способ увеличения эффективности терапии аутоиммунных заболеваний, таких как ревматоидный артрит

Also Published As

Publication number Publication date
PL3078372T3 (pl) 2018-02-28
RS56489B1 (sr) 2018-01-31
EP3078372B1 (en) 2017-09-13
SMT201700080T1 (it) 2017-03-08
US20160228406A1 (en) 2016-08-11
CN105407887A (zh) 2016-03-16
EP2929880B1 (en) 2016-09-14
US20160228404A1 (en) 2016-08-11
RS55394B1 (sr) 2017-04-28
LT2929880T (lt) 2016-11-25
CY1119496T1 (el) 2018-03-07
WO2015008827A1 (ja) 2015-01-22
SI2929880T1 (sl) 2016-12-30
TWI603965B (zh) 2017-11-01
EP2929880A4 (en) 2015-10-14
NO3078372T3 (da) 2018-02-10
IL243550A0 (en) 2016-02-29
EP2929880A1 (en) 2015-10-14
SMT201700080B (it) 2017-03-08
ES2642440T3 (es) 2017-11-16
ES2593527T3 (es) 2016-12-09
EP3078372A1 (en) 2016-10-12
SMT201700606T1 (it) 2018-01-11
CA2918325A1 (en) 2015-01-22
AU2014291149B2 (en) 2017-05-04
RU2641301C2 (ru) 2018-01-17
RU2016105141A (ru) 2017-08-23
HUE029800T2 (en) 2017-04-28
RU2017131951A (ru) 2019-02-06
JP2016034953A (ja) 2016-03-17
PL2929880T3 (pl) 2017-03-31
JP6060231B2 (ja) 2017-01-11
LT3078372T (lt) 2017-11-27
PT2929880T (pt) 2016-11-08
US20150353519A1 (en) 2015-12-10
AU2014291149A1 (en) 2016-02-11
HK1222556A1 (zh) 2017-07-07
RU2017131951A3 (da) 2020-12-18
HUE034661T2 (en) 2018-02-28
JP5802868B2 (ja) 2015-11-04
HRP20161317T1 (hr) 2016-12-16
TW201536764A (zh) 2015-10-01
CA2918325C (en) 2018-06-26
PT3078372T (pt) 2017-10-18
DK3078372T3 (da) 2017-10-16
SI3078372T1 (en) 2018-01-31
CN105407887B (zh) 2018-09-04
CY1118140T1 (el) 2017-06-28
RU2750540C2 (ru) 2021-06-29
JPWO2015008827A1 (ja) 2017-03-02
IL243550B (en) 2019-06-30
HRP20171497T1 (hr) 2017-11-17
US9918963B2 (en) 2018-03-20

Similar Documents

Publication Publication Date Title
IL239960B (en) Calculating a fractional flow reserve
DK2961410T3 (da) Anvendelse af pyrazolopyrimidinderivater til behandlingen af pi3k relaterede lidelser
DK3030323T3 (da) Kdm1a-inhibitorer til behandlingen af sygdom
PL3623002T3 (pl) Cewnik
HUE066955T2 (hu) Nedvszívó struktúra
EP2944185A4 (en) Artificial soil medium
DK3192518T3 (da) Anti-inflammatorisk middel
HRP20180684T1 (hr) Kombinacija lijekova
DK2970389T3 (da) Farmaceutiske forbindelser
HUE042763T2 (hu) Módosított szerpinek vérzési rendellenességek kezelésére
DK3019166T3 (da) A Pharmaceutical Combination for the Treatment of Melanoma
EP3284507C0 (en) CANNULA UNIT
DK3374497T3 (da) Modificerede makrofager til anvendelse i behandlingen af kræft
EP3495938A4 (en) RAID CONFIGURATION
DK3363428T3 (da) Perfusionsdoseringsform
IL258966A (en) Absorbent structure
DK2974728T3 (da) Terapeutisk middel til meibomsk dysfunktion
DK2932944T3 (da) Støtteortose
HRP20181799T1 (hr) Optimizirana farmaceutska formula, namijenjena liječenju upalnih promjena jednjaka
DK3024816T3 (da) Ppar-sparende forbindelser til behandling af metaboliske sygdomme
LT2959892T (lt) Enterine danga padengta tabletė
DK3096775T5 (da) SOCS-mimetika til behandling af sygdomme
DK3058344T3 (da) Fremgangsmåder til måling af carbonhydridfluiders tilsmudsningstendens
LT3324951T (lt) Peritoninis terapinis skystis
DK3089778T3 (da) Ballonkateter